Legend Biotech shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announce an $86 price target.
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech's stock price increased following Raymond James' initiation of coverage with an Outperform rating and an $86 price target.
March 13, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech's shares are expected to see a positive short-term impact due to Raymond James' Outperform rating and $86 price target.
Analyst ratings, especially from reputable firms like Raymond James, can significantly influence investor sentiment and stock prices. The Outperform rating and ambitious $86 price target suggest a strong confidence in Legend Biotech's future performance, likely leading to increased investor interest and a positive short-term price movement.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90